{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:26:24Z","timestamp":1788571584949,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"US-Israel Binational Science Foundation","award":["2015365"],"award-info":[{"award-number":["2015365"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ejps.2017.06.022","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T19:01:44Z","timestamp":1497466904000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Phospholipid-drug conjugates as a novel oral drug targeting approach for the treatment of inflammatory bowel disease"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-3514","authenticated-orcid":false,"given":"Arik","family":"Dahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Aponick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Ben-Shabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ejps.2017.06.022_bb0005","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejps.2017.06.022_bb0010","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1208\/s12249-015-0350-9","article-title":"Colon-targeted oral drug delivery systems: design trends and approaches","volume":"16","author":"Amidon","year":"2015","journal-title":"AAPS PharmSciTech"},{"issue":"Suppl","key":"10.1016\/j.ejps.2017.06.022_bb0015","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1194\/jlr.R800033-JLR200","article-title":"Phospholipase A(2) structure\/function, mechanism, and signaling","volume":"50","author":"Burke","year":"2009","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.ejps.2017.06.022_bb0020","first-page":"33","article-title":"Pharmaceutical approaches to colon targeted drug delivery systems","volume":"6","author":"Chourasia","year":"2003","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2017.06.022_bb0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2006.12.032","article-title":"A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate","volume":"119","author":"Dahan","year":"2007","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ejps.2017.06.022_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.10.025","article-title":"The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration","volume":"126","author":"Dahan","year":"2008","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.ejps.2017.06.022_bb0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1586\/eci.10.30","article-title":"Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update","volume":"6","author":"Dahan","year":"2010","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"8","key":"10.1016\/j.ejps.2017.06.022_bb0040","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/17425247.2012.697055","article-title":"Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach","volume":"9","author":"Dahan","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"issue":"10","key":"10.1016\/j.ejps.2017.06.022_bb0045","doi-asserted-by":"crossref","first-page":"16489","DOI":"10.3390\/molecules191016489","article-title":"Modern prodrug design for targeted oral drug delivery","volume":"19","author":"Dahan","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2017.06.022_bb0050","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2174\/1568026616666160414122913","article-title":"Phospholipid-based prodrugs for drug targeting in inflammatory bowel disease: computational optimization and in-vitro correlation","volume":"16","author":"Dahan","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejps.2017.06.022_bb0055","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2174\/1568026616666160414122913","article-title":"Phospholipid-based prodrugs for drug targeting in inflammatory bowel disease: computational optimization and in-vitro correlation","volume":"16","author":"Dahan","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejps.2017.06.022_bb0060","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1124\/jpet.106.103184","volume":"318","author":"Dvir","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.ejps.2017.06.022_bb0065","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1527-3458.2007.00014.x","article-title":"DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy","volume":"13","author":"Dvir","year":"2007","journal-title":"CNS Drug Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.ejps.2017.06.022_bb0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000341947","article-title":"Topical therapies in inflammatory bowel disease","volume":"86","author":"Frei","year":"2012","journal-title":"Digestion"},{"issue":"8","key":"10.1016\/j.ejps.2017.06.022_bb0075","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s11095-010-0130-x","article-title":"Phospholipids and lipid-based formulations in oral drug delivery","volume":"27","author":"Fricker","year":"2010","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejps.2017.06.022_bb0080","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/ATVBAHA.112.249854","article-title":"Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation","volume":"32","author":"Goncalves","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.ejps.2017.06.022_bb0085","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/gut.40.1.95","article-title":"Gene expression of group II phospholipase A2 in intestine in ulcerative colitis","volume":"40","author":"Haapam\u00e4ki","year":"1997","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.ejps.2017.06.022_bb0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/00365519950185643","article-title":"Phospholipase A2 in serum and colonic mucosa in ulcerative colitis","volume":"59","author":"Haapamaki","year":"1999","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"1","key":"10.1016\/j.ejps.2017.06.022_bb0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1208\/ps020106","article-title":"Targeted prodrug design to optimize drug delivery","volume":"2","author":"Han","year":"2000","journal-title":"AAPS PharmSci"},{"issue":"1","key":"10.1016\/j.ejps.2017.06.022_bb0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0022-5193(88)80124-3","article-title":"Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach","volume":"131","author":"Hu","year":"1988","journal-title":"J. Theor. Biol."},{"issue":"2","key":"10.1016\/j.ejps.2017.06.022_bb0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0009-3084(00)00167-5","article-title":"Drug-phospholipid conjugates as potential prodrugs: synthesis, characterization, and degradation by pancreatic phospholipase A(2)","volume":"107","author":"Kurz","year":"2000","journal-title":"Chem. Phys. Lipids"},{"issue":"3","key":"10.1016\/j.ejps.2017.06.022_bb0110","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/gut.37.3.380","article-title":"Phospholipase A2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis","volume":"37","author":"Lilja","year":"1995","journal-title":"Gut"},{"issue":"1\u20133","key":"10.1016\/j.ejps.2017.06.022_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.ejps.2017.06.022_bb0120","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/gut.35.11.1593","article-title":"Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis","volume":"35","author":"Minami","year":"1994","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.ejps.2017.06.022_bb0125","article-title":"Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer","volume":"9","author":"Peddi","year":"2013","journal-title":"Future Oncol. (London, England)"},{"issue":"5","key":"10.1016\/j.ejps.2017.06.022_bb0130","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/gut.39.5.698","article-title":"Phospholipase A2 activating protein and idiopathic inflammatory bowel disease","volume":"39","author":"Peterson","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.ejps.2017.06.022_bb0135","series-title":"Chapter 5 - Vipoxin and its components: structure\u2013function relationship. Advances in protein chemistry and structural biology","first-page":"117","volume":"Volume 87","author":"Petrova","year":"2012"},{"issue":"2","key":"10.1016\/j.ejps.2017.06.022_bb0140","first-page":"211","article-title":"Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme","volume":"12","author":"Pruzanski","year":"1985","journal-title":"J. Rheumatol."},{"issue":"23","key":"10.1016\/j.ejps.2017.06.022_bb0145","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/eurheartj\/ehs148","article-title":"Phospholipase A2 enzymes and the risk of atherosclerosis","volume":"33","author":"Rosenson","year":"2012","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.ejps.2017.06.022_bb0150","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1080\/17512433.2016.1236681","article-title":"Novel immunotherapy in the treatment of advanced non-small cell lung cancer","volume":"9","author":"Santabarbara","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2017.06.022_bb0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/08941939609012481","article-title":"Secretory phospholipase A2 levels in rat small bowel","volume":"9","author":"Sonnino","year":"1996","journal-title":"J. Investig. Surg."},{"issue":"12","key":"10.1016\/j.ejps.2017.06.022_bb0160","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s008940050065","article-title":"Extraction of lipids from phospholipid membranes by steered molecular dynamics","volume":"3","author":"Stepaniants","year":"1997","journal-title":"Mol. Model. Annu."},{"issue":"5a","key":"10.1016\/j.ejps.2017.06.022_bb0165","first-page":"3179","article-title":"Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue","volume":"27","author":"Tribler","year":"2007","journal-title":"Anticancer Res."},{"issue":"12","key":"10.1016\/j.ejps.2017.06.022_bb0170","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejps.2017.06.022_bb0175","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/01.MP.0000052101.58988.1F","article-title":"COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas","volume":"16","author":"Wendum","year":"2003","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.ejps.2017.06.022_bb0180","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1517\/17425247.2013.800480","article-title":"New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities","volume":"10","author":"Wolk","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2017.06.022_bb0185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.biochi.2015.11.003","article-title":"In vivo imaging of protease activity by Probody therapeutic activation","volume":"122","author":"Wong","year":"2016","journal-title":"Biochimie"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717303561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717303561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T13:25:23Z","timestamp":1582550723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717303561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":37,"alternative-id":["S0928098717303561"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.06.022","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phospholipid-drug conjugates as a novel oral drug targeting approach for the treatment of inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}